

To,

10th October, 2025

Mr. J.P. Nadda,
Minister for Health & Family Welfare,
Government of India, 348-A,
Nirman Bhawan, Maulana Azad Road,
New Delhi – 110 011.

Sir,


Sub: Regarding a public health emergency precipitated by the identification of contaminated mannitol solution at AIIMS, New Delhi

1. By way of introduction, I am a public health activist and the author of the book *The Truth Pill: The Myth of Drug Regulation in India* (Simon & Schuster; 2022).
2. I am writing to you with regard to a recent notice, dated 27th September 2025 by the Medical Superintendent of the All India Institute of Medicine (AIIMS), New Delhi that it was blacklisting a pharmaceutical company by the name of Pentagon Labs Ltd. after parenteral solutions supplied by the company were determined to be contaminated with a fungus. In particular, the blacklisting order has stated that quality testing by the Microbiology Laboratory at AIIMS discovered fungus in five different batches of four different parenteral solutions: dextrose + sodium chloride (5mg + 0.9 mg/100ml (500ml), 5% dextrose, 20% mannitol and 50% dextrose (100 ml). These parenteral solutions are typically administered on patients via the intravenous route meaning that it is generally injected into bloodstream. Any contamination of these parenteral solutions can cause serious adverse reactions, and even death, in patients especially ones who are immunocompromised. A copy of the blacklisting order is attached as Annexure A.
3. The same company also featured in the CDSCO alert published in June, 2025 because a batch of sodium chloride injectables which it had manufactured failed sterility testing in a state drug laboratory run by the Karnataka Drug Control Department. A copy of the drug alert is attached as Annexure B.
4. The fact that six different batches manufactured by the same company have failed quality testing in two different laboratories of the country indicates a catastrophic failure at the manufacturing facility to comply with the Good Manufacturing Practices (GMP) code, especially the requirement for sterile manufacturing facilities to conduct regular environmental monitoring. These failures could include the use of contaminated water, contaminated vials or contaminated equipment. Given these obvious failures to ensure sterility at the manufacturing facility there is a high probability that multiple batches, other than the five already identified at AIIMS and Karnataka, are also contaminated. The presence of these additional batches in other hospitals or pharmacies can have catastrophic costs for public health. Given the possible consequences to public health, I urge the Health Ministry to urgently coordinate a rapid recall of all stocks manufactured by the company still available in the market. This would require a seizure of the sales records of the company in order to identify the recipients of its products. Any delay on this count will most likely lead to more serious adverse events and possibly deaths of patients upon whom these parentals are administered in the near future.
5. I would also like to reiterate the concerns that I had expressed to you in my letter dated December 26, 2024 (Attached as Annexure C) after government hospitals in Jammu and Kashmir reported contaminated injectables containing Bupivacaine Hydrochloride in

Dextrose. As I had mentioned in that letter, contaminated parenteral solutions have been responsible for several deaths in the recent past. This includes the following confirmed incidents:

- January, 2025: Contaminated Ringer Lactase solution manufactured by a pharmaceutical company located in West Bengal is suspected to be the cause of death of two women in a government hospital in West Bengal;
 - November, 2024: Contaminated Ringer Lactase solution manufactured by a pharmaceutical company located in West Bengal is suspected to be the cause of death of 4 young mothers in a government hospital in Karnataka;
 - November, 2023: Contaminated Methotrexate injectables manufactured by Maharashtra based pharmaceutical company are suspected to have caused the deaths of 4 children in Columbia, South America;
 - September, 2022: Contaminated Propofol injections manufactured by a Himachal Pradesh based pharmaceutical company used as an anaesthetic agent during surgeries was identified as the cause of death of 5 patients at PGIMER, Chandigarh;
 - December, 2021: Contaminated Remdesivir injections manufactured by a Gujarat based manufacturer reportedly caused SAEs across a number of states during the pandemic in India;
6. As I had mentioned in my earlier letter it is of absolutely pivotal importance that the Ministry of Health urgently put in place a rapid recall system for contaminated parenteral solutions given the consequences of the same for public health. This should include a mechanism for the Ministry to communicate details of the contaminated batches to the general public, the medical community and pharmacy associations. Such a recall system should also require a team of central drug inspectors to seize the sales records of the contaminated batches and communicate details of the sales records to state drug inspectors who should then be under an obligation to seize and destroy the contaminated batches as per the prevalent environmental rules for disposing medical waste.
7. I hope the Ministry acts quickly on my recommendations so as to prevent any further harm to Indian patients.

Sincerely,



Dinesh Thakur

Annexure A

To

December 26, 2024

Mr. J.P. Nadda,
Minister for Health & Family Welfare,
Government of India, 348-A,
Nirman Bhawan, Maulana Azad Road,
New Delhi – 110 011.


Dear Mr. Nadda,

Sub: Regarding alert issued by Jammu & Kashmir Medical Supplies Corporation Ltd. regarding Bupivacaine Hydrochloride in Dextrose Injection Batch Number AA40222, manufactured by Aishwarya Healthcare Ltd.

1. I write to you with regard to a recent alert issued by the Jammu & Kashmir Medical Supplies Corporation Ltd. (JKMSCL) alerting hospitals to stop using the drug Bupivacaine Hydrochloride in Dextrose Injection Batch Number AA40222, manufactured by Aishwarya Healthcare Ltd. after reports of serious adverse events (SAE) in patients who were administered the injection. This drug is used as a local anaesthetic during a variety of medical procedures ranging from childbirth and maternal health to dentistry. The notice issued by JKMSCL mentions that the injections are suspected to have caused the following SAEs in patients: renal failure, severe hypotension, bradycardia, neurological complications, severe headaches and palpitations with dyspnea. A copy of the notice is annexed herewith as **Annexure A**.
2. While the drug in the above case has been sent for quality testing to laboratories in order to confirm suspicions that it is the cause of the SAEs reported by doctors in Jammu, it is absolutely necessary that the Ministry of Health issue a nation-wide alert requesting hospitals to freeze the use of all injectables manufactured by this company until the results of the investigation are public. It is possible that the reported SAEs have been caused by contamination at the manufacturing facility, indicating a larger failure of quality control systems at the facility. Until an investigation establishes the reason for the SAEs and the possibility of quality control failures, the government should, in the interest of public health, advise hospitals to stop the use of all injectables manufactured by the company in question.
3. Over the last four years, there have been an increasing number of complaints regarding the quality of parenteral drugs being manufactured in India. These drugs which are directly injected into the human body need to be manufactured in absolutely sterile facilities. For example, the water used in the manufacture of these drugs must be of the standard for making sterile injectables, "Water for Injection". If the water used in the manufacture of parenteral drugs is not sterile and of this quality, it can result in SAEs and even deaths. Over the last few years, there have been multiple reports of contaminated parenteral drugs manufactured in India causing deaths and other adverse events amongst patients in India and around the world. A few such cases are listed below:
 - November, 2024: Contaminated Ringer Lactase solution manufactured by a manufacturer located in West Bengal is suspected to be the cause of death of 4 young mothers in Karnataka;

- November, 2023: Contaminated Methotrexate injectables manufactured by a Maharashtra based manufacturer are suspected to have caused the deaths of 4 children in Columbia, South America;
 - September, 2022: Contaminated Propofol injections used as an anaesthetic agent during surgeries was identified as the cause of death of 5 patients at PGIMER, Chandigarh;
 - December, 2021: Contaminated Remdesivir injections manufactured by a Gujarat based manufacturer reportedly caused SAEs across a number of states during the pandemic in India;
4. In addition, there is mounting evidence from quality testing by government laboratories in India that parenteral drugs, especially injectables, are failing at alarming rates. For example, on 27 February 2024 the Health Minister of Himachal Pradesh informed the Legislative Assembly that over the previous three years, more than 1,600 drugs manufactured in Himachal Pradesh had failed randomised testing in government laboratories. Of these failures, 150 drugs were injectables i.e. almost 10% of the drugs that failed testing. This figure does not include other parenteral drugs such as infusions and solutions administered intravenously. The number of such NSQ drugs is possibly much higher in our drug supply. A copy of the answer provided to the Legislative Assembly is attached as **Annexure B**.
5. Given the mounting numbers of parenteral drugs failing quality tests, the increasing number of deaths over the last 4 years and the recent incident in Jammu, I request you to order the Health Secretary to take the following actions immediately:
- Communicate to the general public and medical community about the failure of the drug identified by JKMSCL instructing them to not consume any drugs manufactured by the company in question until an investigation establishes whether the drug caused the SAEs in question;
 - Establish a nationwide system of rapid alerts and recalls for parenteral drugs that fail testing in government laboratories;
 - Institute an expert committee of pharmacologists and medical doctors to study the extent of quality failures with parenteral drugs in India and identify reasons for the same so that the Ministry of Health may put in place a strategy to improve the quality of these crucial drugs;

Sincerely,



Dinesh Thakur

Encl.: Annexures A & B



JAMMU AND KASHMIR MEDICAL SUPPLIES CORPORATION LTD.

(Public Sector Undertaking of Govt of Jammu & Kashmir)

Corporate Head Office: 1st Floor, Drug Store Building, Govt. Medical College, Bakshi Nagar, Jammu

(Temporary shifted to Plot No 58, Friends Colony, Satyam Road, Trikuta Nagar, Jammu)

Corporate Office Kashmir: Opposite State Motor Garages, Bemina Srinagar

Telephone: 0191-2580842, Fax: 0191-2581845 (Jammu); Telefax: 0194-2432008 (Srinagar)

**The Medical Officer (All),
I/c Regional Drug Warehouses,
JKMSCL (J&K).**

Most Urgent

NO: -JKMSCL/QC/J/2024-25/ **3750 - 55**

Dated: - 23-12-2024

Sub:- Stop Use Notice of Bupivacaine Hydrochloride In Dextrose Inj. USP (0.5%) 5mg/ml 4ml Amp.; Batch No: AA4022; D.O.Mfg.:- Apr/2024; D.O.Exp.:- Mar/2026; Mfg. by: - M/s Aishwarya Healthcare Ltd.

Ref:- Block Medical Officer Sopore letter no:-Estt/SDH/Spr/3263, dated:-19-12-2024.


Sir/Madam,

In view of the Adverse Drug Reaction (ADR) reported with Bupivacaine Hydrochloride In Dextrose Inj. USP (0.5%) 5mg/ml 4ml Amp., Batch no: - **AA4022**, manufactured by:- M/s Aishwarya Healthcare Ltd, it is directed to stop the use of said batch of drug with immediate effect.

Matter may be accorded top priority.

Encl: - 02 leaves

Yours faithfully


Medical Officer,
Quality Control Section,
JKMSCL, Jammu.

Copy to the:-

1. MD, JKMSCL for favour of information.
2. FA/CAO, JKMSCL for Information.
3. GM (ADM), JKMSCL for Information.
4. GM (P&S), JKMSCL for Information.
5. DGM (IT), JKMSCL for Information



UNION TERRITORY OF JAMMU & KASHMIR
OFFICE OF THE
BLOCK MEDICAL OFFICER SOPORE
Office: Sub District Hospital Sopore. Pin: 193201,
Telephone: 01954220800; e-mail: bmosopore111@gmail.com



The Block Medical Officer
SDH Sopore.

No:-Estt/SDH/Spr/ 3262

Dated:- 19-12-2024

Subject: - Report regarding the Anesthetic drug (Inj. Bupivacaine).

Sir,

Kindly refer to the subject in this context it is submitted that the mentioned drug under the brand name of Bupivacaine Hydrochloride in dextrose Inj. batch no :AA4022 manufacture date 04-2024 Exp. date 03/2026 manufactured by the Aishwariya Health care of JKMSCL Hospital Supply has been used for the period of 02 months and have observed the following points.

01. Many patients develop severe hypotension and bradycardia by using the usual dosage for spinal Anesthesia.
02. Many patients develop acute renal failure in immediate post operative period during the past two month.
03. Many patients develop severe Headache and palpitation with dyspnea in post operative period.
04. Recently had one episode of Neurological complication immediately after spinal anesthesia for which patient was referred to tertiary care Hospital.

Now in view of above complication's the last one being more serious one, we have stopped the usage of above mentioned drug.

Hence the report is submitted to your goodself for favour of information and further necessary action at your end.

Yours faithfully

Dr Sameer Ibrahim
Dr Khalida Parveen.
Dr Sameena Akhter.
Dr Kashif Hassan Bhat
Dr Arif Amin Bhat

[Handwritten signatures]
Khalida Parveen
Sameena Akhter
Kashif Hassan Bhat
Arif Amin Bhat

[Handwritten signature]
Block Medical Officer
Sopore

विभाग का नाम:	स्वास्थ्य एवं परिवार कल्याण
प्रश्न संख्या तारांकित:	1585
उत्तर की तिथि:	27.02.2024
विषय:	दवाइयों के सैम्पल
प्रश्नकर्ता:	श्री केवल सिंह पटानिया (शाहपुर): श्री विपिन सिंह परमार (सुलह):
सम्बन्धित मन्त्री:	स्वास्थ्य एवं परिवार कल्याण मन्त्री।

प्रश्न	उत्तर
<p>क्या स्वास्थ्य एवं परिवार कल्याण मंत्री बतलाने की कृपा करेंगे कि:-</p> <p>(क) वर्तमान में प्रदेश में कुल कितनी फार्मा यूनिट कार्यरत हैं;</p> <p>(ख) गत तीन वर्षों में दिनांक 15.01.2024 तक इनमें बनाई जाने वाली कितनी दवाइयों के सैम्पल फेल हुए हैं; कम्पनियों के नाम सहित ब्यौरा दें;</p> <p>(ग) जिन कम्पनियों की दवाइयों के सैम्पल फेल हुए हैं, उन पर सरकार द्वारा क्या कार्रवाई की गई;</p> <p>(घ) बी0बी0एन0 क्षेत्र में कितनी फार्मास्यूटिकल्स दवाइयां तैयार की जाती हैं व कितनी दवाइयों के सैपल गत वर्ष में फेल हुए तथा जिन दवाइयों के सैपल फेल हुए उन कंपनियों पर सरकार द्वारा क्या कार्रवाई की गई; और</p> <p>(ङ) दवाइयों की गुणवत्ता जाँच हेतु सरकार द्वारा क्या मापदंड अपनाए जाते हैं; ब्यौरा फार्मास्यूटिकल्स कम्पनी व दवाइयों के नाम सहित दें?</p>	<p>(क), (ख), (ग), (घ) एवं (ङ) सूचना सभा पटल पर रख दी गई है।</p>

तारांकित विधान सभा प्रश्न संख्या: 1585 जोकि श्री केवल सिंह पठानिया (शाहपुर) व श्री विपिन सिंह परमार (सुलह) द्वारा दवाइयों के सैंपल बारे पूछा गया है का उत्तर:-

(क) प्रदेश मे कुल 677 फार्मा युनिट स्थापित है।

(ख) एवं (ग)

गत तीन वर्षों (जनवरी, 2024) तक में जिन कम्पनियों के दवाइयों के सैंपल फेल हुए हैं, कम्पनियों के नाम तथा उन पर सरकार द्वारा की गई कार्रवाई का ब्यौरा निम्न प्रकार से हैं:-

Sr. No	Name of the Firm	District in which firm is located	Sample Name	Batch Number	Action Taken
1	Abbott Healthcare Pvt. Ltd	Solan	Gardenal-30 Tablets	GDA8005	Sample Passed by CDL Kolkata
2	Acme Generics LLP	Solan	Chymocip Tabs.	G19CHP004	Sent to the concerned State for sample portion
3	Acme Generics LLP	Solan	Dollprane ^R 500 Tablets	ADG0069	Challenged
4	Acme Generics LLP	Solan	Thyronorm 100mg Tablets	AEG1233 & AE4104	Spurious
5	Acme Generics LLP	Solan	Thyronorm 100mcg Tablets	AEF4104,AEG135 2, AEG2017 AEG1233	Spurious
6	Acme Life Tech LLP	Solan	Atozine -10 Tablets	ALT19905	Product permission suspended for 01 Month
7	Actinova Pvt Ltd	Solan	Acitek-150 Tablets	AT1A020	Product permission suspended for 01 Month
8	ADDII Biotech	Solan	Ashtapan DSR Capsules	AC2001011	Product permission suspended for 01 Month
9	Addii Biotech Pvt Ltd	Solan	Glims-MP2 Tablets	AT2005110	Product permission suspended for 01 Month
10	Addii Biotech Pvt Ltd	Solan	Famflu Tablets	At2004096	Product permission suspended for 01 Month
11	Affy Parenterals	Solan	Culite Cream 15gm	PB198	Product permission suspended for 03 months
12	Affy Parenterals	Solan	NerviXPS Capsules	PSG20372	Product permission suspend for 03 months
13	Aishwarya Healthcare	Solan	Budelife Respules Suspension	RS0059	Product permission suspended for 15 Days
14	Aishwarya Healthcare	Solan	BUPICORT 0.5MG/2ML	RS1071	Product permission suspended for 20 days

S.No	Name of the Firm	District in which firm is located	Sample Name	Batch Number
360	DM Pharma Pvt. Ltd	Rednil Tablets	DMT1197B	Show cause Notice issued, Under Correspondance
361	Health Biotech Ltd	PICOZONE Injection	HICO23010A	Show cause Notice issued, Under Correspondance
362	Health Biotech Ltd	A-CAINE Injection	HILA23013C	Show cause Notice issued, Under Correspondance
363	Alliaance Biotech	Heparin Sodium Injection IP 5000 IU/5ml	AGI-23112	Show cause Notice issued, Under Correspondance
364	Alliaance Biotech	Heparin Sodium Injection IP 5000 IU/5ml	AGI-23108, AGI-23109, AGI-23110, AGI-23111, AGI-23113 & AGI-23114	Show cause Notice issued, Under Correspondance
365	Innova Captab Ltd	Magnakof-LS Syrup	FHVAM011	Show cause Notice issued, Under Correspondance
366	Aquinova Pharmaceuticals	Cypermed Syrup	AQC2339A	Under Investigation
367	Pragati Remedies	C-Cef OLB Tablets	SLH-2101	Legal Action Taken
368	GGs Pharmacy	Loose round tablets purported cefpodoxime Proxetil	XBT003939	Legal Action Taken
369	Lifevision Healthcare Pvt. Ltd	Bromex AF Syrup	LLD-302	10 Days
370	Maiden Pharmaceuticals	CSP Syrup	LOCG21-85	Under Investigation
371	Maiden Pharmaceuticals	CSP Syrup	LOCG21-96	Under Investigation
372	Maiden Pharmaceuticals	CSP Syrup	LOCG21-84	Under Investigation
373	Maiden Pharmaceuticals	CSP Syrup	LOCG21-95	Under Investigation
374	Maiden Pharmaceuticals	CSP Syrup	LOCG21-94	Under Investigation

(ड) दवाईयों की गुणवत्ता जाँच हेतु औषधि एवं प्रसाधन अधिनियम, 1940 में निहित प्रावधानों अनुसार समय-समय पर दवा निरीक्षकों द्वारा सैम्पल/नमूने लिए जाते हैं, तथा इनकी गुणवत्ता की जाँच हेतु प्रदेश में स्थिति सयुक्त परीक्षण प्रयोगशाला, कण्डाघाट के साथ प्रदेश सरकार द्वारा अधिकृत क्षेत्रीय परीक्षण प्रयोगशाला चण्डीगढ़ में इन नमूनों की जाँच की जाती है। यदि दवा के सैम्पल की रिपोर्ट निर्धारित मानकों के विरुद्ध आती है तो उनके खिलाफ औषधि एवं प्रसाधन अधिनियम, 1940 के प्रावधानों अनुसार कार्रवाई की जाती है।

प्रदेश सरकार द्वारा भारत सरकार की सहायता से बर्ददी में दवा परीक्षण प्रयोगशाला का निर्माण किया जा रहा है ताकि अधिक संख्या में दवा के सैम्पलों की जांच की जा सके और प्रदेश में किसी भी प्रकार की घटिया दवा के

निर्माण और वितरण पर पूर्ण रूप से अंकुश लगाया जा सके। विभाग में 39 औषधि निरीक्षक हैं जो इन विनिर्माण इकाइयों, बिक्री परिसरों और सरकारी अस्पतालों का निरीक्षण कर रहे हैं। विनिर्माण इकाइयों का नियमित रूप से निरीक्षण किया जा रहा है ताकि यह सुनिश्चित किया जा सके कि ये इकाइयां अच्छी विनिर्माण प्रथाओं (Good Manufacturing Practices) यानि अनुसूची 'M' के सम्बन्ध में औषधि और सौंदर्य प्रसाधन अधिनियम के प्रावधानों का अनुपालन करें। यदि कोई इकाई इस अधिनियम का उल्लंघन करती है तो उसके खिलाफ नियमानुसार कार्यवाही की जाती है।

जहां तक बी0बी0एन0 क्षेत्र में स्थित दवा कम्पनियों की फार्मास्युटिकल कम्पनियों की गुणवत्ता जांच का प्रश्न है तो इस बारे अवगत करवाया जाता है कि सभी दवा कम्पनियों की गुणवत्ता हेतु औषधि एवं प्रसाधन अधिनियम,1940 में निहित प्रावधानों अनुसार कार्रवाई की जाती है।

Annexure B

B. NOT OF STANDARD QUALITY ALERT FOR THE MONTH OF JUNE– 2025 (STATE LABORATORIES)

As part of the continuous regulatory surveillance, Drugs/Cosmetics/Medical Devices samples are picked from sales/distribution point, analyzed and list of Not of Standard Quality (NSQ) drugs are displayed on CDSCO portal on monthly basis. The purpose of displaying the NSQ list is to make stakeholders aware about the NSQ batches identified in the market.

S.No	Product/Drug Name	Batch No.	Manufacturing Date	Expiry Date	Manufactured By	NSQ Result	Reported by State Laboratory
1.	Lorazepam Tablets I.P (1 mg)	3305	Apr-24	Mar-28	M/s. Reliance Formulation Pvt. Ltd., 7/2-A, G.I.D.C. Estate, Phase-1 Vatva, Ahemedabad-382445	Assay for Lorazepam” and “Dissolution Test	Karnataka
2.	Telapp MT 25 (Telmisartan & Metoprolol Succinate (ER) Tablets)	T24H459A	Aug-24	Jul-26	M/s. Bajaj Formulation, Khasra No.161, Village-Lakeshwary Bhagwanpur, Roorkee Distt: Haridwar (UK)	Assay for Metoprolol Tartrate	Karnataka
3.	Pantrum-40 Tablets (Pantoprazole Gastro-Restant Tablets IP)	HT24686	Aug-24	Jul-26	M/s. Habitare Pharma pvt. Ltd., Plot No.43-44, Industrial Estate, HSIIDC, Alipur, Barwala, Distt. Panchkula (HR)-134118	Dissolution” and “Description	Karnataka
4.	Frusemide Injection I.P. 2 ml (Rasix Injection)	IFMI415	Sep-24	Aug-26	M/s. Regain Laboratories, 134/5 H.T.M. Road., Raipur Lane Hisar-125001	pH” and Sterility	Karnataka
5.	Methotrexate Injection IP 15 mg/ml (Folitrax-15)	AI054J24	Sep-24	Aug-26	M/s. BDH Industrial Ltd., Nair Baug, Akurli Road, Kandivil (E) Mumbai-400101	Sterility	Karnataka
6.	Paracetamol Tablets I.P 500 mg	2511723	Feb-23	Jan-26	M/s. Karnataka Antibiotics & Pharmaceuticals Ltd., Plot No.14, II Phase, Peenya Industrial Area, Bengaluru-560058	Description	Karnataka
7.	Iron Sucrose Injection USP (Irolink Injection),	L0372321C	Oct-23	Sep-25	M/s. Protech Telelinks, Mauza Ogli, Suketi Road Kala Amb, Distt. Sirmour-173030 (H.P)	Sterility	Karnataka
8.	Dexamethasone Sodium Phosphate Injection I.P (Dexasun-For IM & IV use only)	HLI380C	Mar-24	Feb-26	M/s. Himalaya Meditek (P) Ltd., Plot No. 35 & 36, Pharmacy, Selaqui Industrial Area, Dehradun-248197	Sterility and Assay for Dexamethasone Phosphate	Karnataka
9.	Oxytetracycline Dihydrate Inj. I.P. (OXY-LA Injection Vet.)	OTL-4449	Nov-24	Oct-26	M/s. Biograde Organics Pvt. Ltd., (AN ISO 9001:2015 & GMP Certified Company), Village Noorwala, Hosiery Complex, Ludhiana (Pb)-141007	Description	Karnataka

10.	Telmisartan and Hydrochlorothizide Tablets I.P (40mg/12.5mg)	TMHT-1037	Oct-23	Sep-26	M/s. Wings Biotech LLP, 43 & 44, HP SIDC, Industrial Area, Baddi-173205 (H.P)	Uniformity of Weight	Karnataka
11.	Telmisartan & Amlodipine Tablets I.P. (Telmamet AM)	KTT24936	Oct-24	Sep-26	M/s. Kantil Pharmaceuticals Pvt. Ltd., Vill, Sainimajra, tehsil Nalagarh, Distt Solan Himachal Pradesh-174101	Dissolution	Karnataka
12.	Lorazepam Tablets IP 2 mg (Proline-2)	05P23T03	Mar-23	Feb-27	M/s. Shine Pharmaceuticals Limited., Plot No. 132, Karjan-Vemardi Road, Juni Jitherdi, Ta. Karjan-391240 Dist: Vadodara (Gujarat)	Assay for Lorazepam	Karnataka
13.	Salbrox-XI Syrup (Ambroxol, Levosalbutamol, Guaiphenesin & Menthol Syrup)	BTB2404	Oct-24	Sep-26	M/s. MMC Healthcare Ltd., No.34-B, SIDCO Industrial Estate, Thirumazhisai, Chennai-600124,	Description	Karnataka
14.	Dextrose Injection I.P 5% w/v (D5)	04BF0660	Sep-23	Aug-26	M/s. Paschim Banga Pharmaceuticals, (A Unit of Farista Vanijya Pvt. Ltd), NH-31, TIN MILE HAT, Sonapur HAT, PS. Chopra Dist. Uttar Dinajpur-733214 (W.B)	Sterility	Karnataka
15.	Sodium Chloride Injection I.P (0.9%w/v)NS	01AF0301	Dec-23	Nov-26	M/s. Paschim Banga Pharmaceuticals, (A Unit of Farista Vanijya Pvt. Ltd), NH-31, TIN MILE HAT, Sonapur HAT, PS. Chopra Dist. Uttar Dinajpur-733214 (W.B)	Sterility	Karnataka
16.	Lilion-MR Tablets (Aceclofenac, Paracetamol & Chlorzoxazone Tablets)	CCT24984B	Jul-24	Jun-26	M/s. Cent Cure Pvt. Ltd., (A WHO-GMP Certifid Company), Plot No.71, DIC, Industrial Area, Vill. Ladhimajra, Tehsil Baddi, Distt. Solan (H.P)-173205	Assay for Aceclofenac and Chlorzoxazone	Karnataka
17.	Methotrexate Injection IP 15 mg/ml (Folitrax-15)	AI071L24	Nov-24	Oct-26	M/s. BDH Industrial Ltd., Nair Baug, Akurli Road, Kandivil (E) Mumbai-400101	Sterility	Karnataka
18.	Atropine Sulphate Injection I.P (Curopine)	AS-1460	Jan-25	Dec-26	M/s. Pharma Cure Laboratories, Garha, Jalandhar-144022,	Sterility	Karnataka
19.	Sodium Chloride Injection I.P (NS)	24EC721	Jul-24	Jun-26	M/s. Pentagon Labs Ltd., 16C/16D, Industrial Area No.1, A.B. Road, Dewas-455001 (M.P)	Sterility	Karnataka
20.	Sodium Chloride Injection IP 0.9% w/v (NS)	TI204A002	Sep-24	Aug-27	M/s. Puniska Injectables Pvt. Ltd., Plot No.1, Phase III, Honda Industrial Estate, Honda Sattari, Goa-403530, India.,	Sterility	Karnataka

21.	Sodium Chloride Injection IP 0.9% w/v (NS)	TI404B024	Sep-24	Aug-27	M/s. Puniska Injectables Pvt. Ltd., Plot No.1, Phase III, Honda Industrial Estate, Honda Sattari, Goa-403530, India	Sterility	Karnataka
22.	Sodium Chloride Injection IP 0.9% w/v (NS)	UB404B021	Feb-25	Jan-28	M/s. Puniska Injectables Pvt. Ltd., Plot No.1, Phase III, Honda Industrial Estate, Honda Sattari, Goa-403530, India	Sterility	Karnataka
23.	Pheniramine Maleate Injection IP (Care Vil)	401	Jul-24	Jun-26	M/s. Carewin Pharmaceuticals (GUJ.) Pvt Ltd., 38, Saket Ind., 38, Saket Ind. Estate-II, N.H.No.8A, P.O. Moraiya, Ta. Sanand, Ahmedabad	Sterility	Karnataka
24.	Paracetamol Tablets IP 500mg	PCTJ23058	Nov-23	Oct-25	M/s. Vivek Pharmachem (India) LTD, EPIP, Bari- Brahmana, Jammu-181133	Description	Karnataka
25.	Mupirocin Ointment IP (Mupifit)	2410223B	Oct-24	Sep-26	M/s. Biodeal Pharmaceuticals Limited, Vill. Sainimajra, Nalagarh- Ropar Road, Nalagarh-174101, Dist. Solan (H.P) India	Identification	Karnataka
26.	Dexamethasone Tablets I.P.0.5 mg,	PP/190	Jun-24	May-26	M/s. Penta Pharmaceuticals, Plot No.16/2/3, Shakti Ind. Est. Rakholi, Silvassa-396230. India	Assay of Dexamethasone	Karnataka
27.	Pantus-D (Pantoprazole & Domperidone Tablets)	APT-23918	Mar-24	Feb-26	M/s. ABOD Pharmaceuticals, Plot No.18-C, Khasra No.150-151, IP-4 Begumpur, Bahadradab, Haridwar-249402	Assay of Pantoprazole	Karnataka
28.	Ciprofloxacin Hydrochloride Tablets IP 250 mg.	CPT24046	Jul-24	Jun-26	M/s. Vivek Pharmachem (India) Ltd., NH-8, Chimanpura, Amer, Jaipur-302028	Dissolution	Karnataka
29.	Sodium Chloride Injection IP 0.9% w/v (NS)	TL504E006	Nov-24	Oct-27	M/s. Puniska Injectables Pvt. Ltd., Plot No.1, Phase III, Honda Industrial Estate, Honda Sattari, Goa-403530, India.	Sterility	Karnataka
30.	ByGo Solution (Povidone Iodine Solution IP)	NM860	Jul-24	Jun-26	M/s. Neptune Life Science Pvt Ltd., 100-B, EPIP, Phase-II, Thana, Baddi-173205 (H.P) India	pH & Assay	Karnataka
31.	Epproz-50 (Eperisone HCl Tablets)	VEOT-2401	Mar-24	Feb-26	M/s. Verax Life Science Pvt Ltd., Khasra No. 435, Village suraj Majra, N.H.21, Baddi, Tehsil Nalagarh, Dist Solan, H.P-173205. India	Assay and Dissolution test for Eperisone HCl	Karnataka
32.	Acivave (Anesthetic, Antacid & Antiflatulent oral Suspension)	EL24165	Mar-24	Feb-26	M/s. Edkem Pharmaceuticals Ltd, M 9-M12, Gallops Industrial Park-II, Chancharvadi- Vasna, bavla-	Assay for Oxethazaine	Karnataka

					Changodhar Highway, Ahmedabad-382210		
33.	Sodium Chloride Injection IP 0.9% w/v (NS)	UA404B021	Jan-25	Dec-27	M/s. Puniska Injectables Pvt. Ltd., Plot No.1, Phase III, Honda Industrial Estate, Honda Sattari, Goa-403530, India	Sterility	Karnataka
34.	Calcium and Vitamin D3 Tablets IP (GENIBONE-500)	HCL5011	Jan-25	Dec-26	M/s. Hanuchem Laboratories, Plot No.15-16-17, Sector-5, Indl. Area, Parwanoo, Dist. Solan (H.P)-173220	Description	Karnataka
35.	Diphenhydramine Hydrochloride Capsules IP 25 mg	C 364	Feb-24	Jan-26	M/s. Bittu Pharmaceuticals (II), Plot No.48, Vasai, Municipal Ind Area, Umela Phata, Dhovali Village, Papdi, Vasai (W), Dist, Palghar-401207 (M.S)	Dissolution	Karnataka
36.	Coxmyth-60 Tablets, (Etoricoxib Tablets IP 60mg)	ZRST-1325	Jul-24	Jun-26	M/s. ZRS Pharmaceuticals India Pvt. Ltd, Khasra No 481,490/3, 562/489/1, Opposite Sector-6, Tehsil Kasauli, Parwanoo, Solan, Himachal Pradesh	Assay for Etoricoxib	Karnataka
37.	Coxmyth-90 Tablets, (Etoricoxib Tablets IP 90mg)	DEMT-242366B	Nov-24	Oct-26	M/s. Dr. Edwin Medilabs Pvt Ltd., Plot No.B-29, Industrial Area, Focal Point, chanalon, Kurali, SAS nagar PB	Uniformity of Weight and Dissolution Test for Etoricoxib	Karnataka
38.	Enrofloxacin Tablets (Enrogen-500)	TEG24004	Dec-24	Nov-26	M/s. Indian Genomix Pvt. Ltd., Plot No. 135/1 & 135/2, Phase-II, I.D.A, Cherlapally, Hyderabad-500051, T.S	Description	Karnataka
39.	Ciprox-TZ Suspension - Vet (Ciprofloxacin and Tinidazole Oral Suspension)	CTL184	Oct-24	Sep-26	M/s. Mahendra Labs Pvt. Ltd.,371 & 372, 4th Phase , Peenya Industrial Area, Bengaluru-560058	Assay for Tinidazole	Karnataka
40.	Grafi clav 625 Tablets (Amoxicillin & Potassium Clavulanate Tablets IP)	TB24-0753A	Nov-24	Apr-26	M/s. Athens Life Sciences, Mauza Rampur, Jattan, Nahan Road, Kala Amb, Distt. Sirmour, H.P-173030	Uniformity of Weight of Tablets	Karnataka
41.	Ibuprofen Tablets IP 400 mg	310524-BKN13	May-24	Apr/2026	M/s. Biogenetic Drugs Pvt. Ltd., Vill. Jharmazri, Baddi-174103, Dist. Solan, H.P.,	Dissolution of Ibuprofen	Karnataka
42.	Ibuprofen Tablets IP 400 mg	270524-BKN13,	May-24	Apr-26	M/s. Biogenetic Drugs Pvt. Ltd., Vill. Jharmazri, Baddi-174103, Dist. Solan, H.P.	Dissolution of Ibuprofen	Karnataka
43.	CIPLOXVET BOLUS (Cephalexin Bolus 1500 mg)	CPT-24007	NOV/2024	Oct-27	M/s. Vet-needa Labs, #4, Karihobanahalli Village, Adjacent to Maruti Indl. Town, Peenya 3rd Stage, 4th Block, Bengaluru-560058	Disintegration	Karnataka

44.	Albendazole Tablets IP 400 mg	ZL70	Oct-23	Sep-26	M/s. Mahendra Labs Pvt. Ltd., 371 & 372, 4th Phase , Peenya Industrial Area, Bengaluru-560058	Dissolution	Karnataka
45.	OFLOVEE OZ (Ofloxacin and Ornidazole Tablets IP)	CT24100	Jun-24	05/2027	M/s. Century Nova Drugs Pvt. Ltd., 85-86, Phase-II, A.K.V.N Industrial Area, Umaria-Dungaria-482003	Description & Assay for Ofloxacin	Karnataka
46.	Nexikam-Plus Tablets (Escitalopram Oxalate & Clonazepam Tablets IP)	GENT9932	Dec-24	Nov-26	M/s. Gentech Healthcare Pvt. Ltd., 1470, HSIIDC Rai-131029, (India)	Uniformity of Content for both Escitalopram Oxalate & Clonazepam	Karnataka
47.	Telmisartan and Hydrochlorothiazide Tablets I.P (40mg/12.5 mg)	TMHT-1012	Sep-23	Aug-26	M/s. Wings Biotech LLP, 43 & 44, HP SIDC, Industrial Area, Baddi- 173205 (H.P)	Uniformity of weight	Karnataka
48.	Cyanocobalamin I.P.- Cynoder Injection I.P. (VITAMIN B12 INJ)	AM-362	Oct-24	Sep-26	M/s. SVP Life Sciences, C/10-1, Sara Industrial Estate Selaqui, Dehradun, Uttarakhand	Sterility” and “Assay for Anhydrous Cyanocobalamin	Karnataka
49.	Sodium Chloride Injection IP 0.9% w/v (NS)	TL104A060	Nov/2024	Oct-27	M/s. Puniska Injectables Pvt. Ltd., Plot No.1, Phase III, Honda Industrial Estate, Honda Sattari, Goa-403530, India	Sterility	Karnataka
50.	Telmisartan and Hydrochlorothiazide Tablets I.P. (40mg/12.5mg)	TMHT1046	Oct/2023	Sep-26	M/s. Wings Biotech LLP, 43 & 44, HP SIDC, Industrial Area, Baddi- 173205 (H.P)	Uniformity of Weight	Karnataka
51.	Rodal 650 (Paracetamol IP 650 mg Tablets)	ARDL-6-2403	Sep-24	Aug-27	M/s. Konis Pharmaceuticals Pvt. Ltd., Jagriti Sadan, Subathu Road, Solan-173212 (H.P)	Dissolution of Tablets, Uniformity of weight and content of Paracetamol in the Assay	Karnataka
52.	Ofloxacin and Dexamethasone Ophthalmic Solution	VE4111	Nov-24	Oct-26	M/s. Alpa Laboratories Ltd., 33/2, A.B. Road, Pigdamber-453446 , Indore (M.P)	Sterility	Karnataka
53.	Pantoprazole Sodium for Injection (Petalife-40)	ABGJ24032TH	Oct-24	Sep-26	M/s. Associated Biopharma Pvt. Ltd., Khasra No 121 Min,122 Min, Sidco Industrial Complex, Pandrar Ghatti, Nanan Kathua, J & K- 184143	Sterility	Karnataka
54.	Frusemide Injection IP- 2ml	24BTH96	Aug-24	Jul-26	M/s.SVP Life Sciences, C/10-1, Sara Industrial Estate, Selequi, Dehradun.	Assay for frusemide	King Institute of Preventive Medicine & Research, Guindy, Chennai-32
55.	Labetalol Tablets IP 100mg	LA1TE012	Aug-24	Jul-26	M/s.Unicure India Ltd, Plot No.46(B)/49B, Vill, Raipur, Bhawanpur, Roorkee, Distt, Haridwar, Uttarakhand	Dissolution of Labetalol Hydrochloride Tablets	Drugs Testing Laboratory, Chennai- 06

56.	Macro Ampicloxa (Ampicillin & Cloxacillin Capsules)	C-20404	Feb-24	Jan-26	M/s.Jackson Laboratories Pvt.Ltd, Plot No,56&61, Industrial Area, Phase-III, Sansarpur, Terrace (H.P)	Content of Ampicillin in Ampicillin Trihydrate and Cloxacillin in Cloxacillin Sodium	Drugs Testing Laboratory, Madurai-19
57.	Co-Trimoxazole Tablets IP 480mg	MT403	Jan-24	Dec-26	M/s.Maxwell Life Science Pvt. Ltd, T-53 & T-81, M.I.D.C, Tarapur, Boisar, Dist.Palghar, 401506	Dissolution for Sulphamethoxazole	Drugs Testing Laboratory, Chennai-06
58.	DKOF-LA Syrup (Ambroxol Hydrochloride, Levocetirizine Hydrochloride, Guiaphenesin & Menthol Syrup)	L1774009	Sep-24	Aug-26	M/s.Innova Cap Tab Ltd, 1281/1, Hiltop Industrial Estate, Near EPIP, Phase-1, Jharmajri, Baddi, District Solan (H.P), India	Content of Ambroxol Hydrochloride	Drugs Testing Laboratory, Chennai-06
59.	Pulmonex-AS (Ambroxol Salbutamol Guaiphenesin Syrup)	HTD-24109	Aug-24	Jul-26	N/A	Content of Salbutamol in Salbutamol Sulphate and Ambroxol Hydrochloride. Note: Manufacturer's Name is not stated on the label.	Drugs Testing Laboratory, Chennai-06
60.	Azithromycin Suspension IP	BGL24257	Oct-24	Sep-26	M/s.Bestcare Formulations Pvt Ltd, Plot No.B-15 & 16, PIPDIC Electronic Park, Thirubhuvanai, Puducherry-605107	pH and the content of Azithromycin.	Drugs Testing Laboratory, Madurai-19
61.	Lecetwin (Levocetirizine Hydrochloride Syrup)	LWLS-2022	Sep-24	Aug-26	M/s.Wings Novitas Healthcare LLP, 43 & 44, HPSIDC, Industrial Area, Baddi-173205 (H.P)	Content of Levocetirizine Hydrochloride	Drugs Testing Laboratory, Chennai-06
62.	Betamethasone Valerate Ointment IP 0.1% w/w	B82	Aug-24	Jul-26	M/s.Syndicate Pharma, 185/B, 185/B-1, 187/A & 188 Sector - F, Sanwer Road, Indore-452015	Content of Betamethasone in Betamethasone Valerate	Drugs Testing Laboratory, Chennai-06
63.	Sepsadone 5% Ointment (Povidone-Iodine Ointment USP 5.0%w/w)	DP-4259	Aug-24	Jul-26	M/s.Daffohils Laboratories Pvt Ltd, F-109-110, UPSIDC Industrial Area, Selaqui, Dehradun (U.K). 248011, (India).	Content of Available Iodine in Povidone-Iodine	Drugs Testing Laboratory, Chennai-06
64.	Dicyclomine Tablets IP	THY24010AL	Aug-24	Jul-26	M/s.Hindustan Laboratories Limited, Plot No. 5-9, Survey No.38/2, Aliyali, Palghar (W), Dist. Palghat 401404 (M.S)	Description.	Drugs Testing Laboratory, Madurai-19
65.	Calamine Lotion IP	2451	Jul-24	Jun-26	M/s.Oscar Remedies Pvt Ltd, Oscar House, Badi Majra, Yamuna Nagar-135001 (HR)	Content of zinc oxide	Drugs Testing Laboratory, Chennai-06
66.	Vitamin B Complex with vitamin C (softgels)	G03724	Apr-24	Mar-26	M/s.Asoj Soft Caps Pvt Ltd, Asoj. Baroda-Halol Highway, Dist. Baroda-391510.Gujarat.	Content of all soft gelatine capsule have leaked and adhere to the strips making it impossible to take average net content	Drugs Testing Laboratory, Madurai-19

67.	Acceclofenac Tablets IP 100mg	AF24009	Sep-24	Aug-26	M/s.Eurokem Laboratories Pvt ltd, C-25, SIDCO Pharmaceutical Complex, Alathur, Thiruporur, 603110.	Content of Aceclofenac	Drugs Testing Laboratory, Madurai-19
68.	Clonit-S (Clobetasol Propionate and Salicylic Acid Ointment)	CS48	11/2024	10/2027	M/s.Karlin Pharmaceuticals & Exports Private Limited, No.2/140, Indira Nagar, Valasaravakkam, Chennai-600087	Content of Clobetasol Propionate and Salicylic Acid	Drugs Testing Laboratory, Madurai-19
69.	Mobyle Gel (Diclofenac Diethylamine, Linseed Oil, Menthol and Methyl Salicylate Gel)	GX027	Jun-24	May-26	M/s.SGS Formulation Pvt Ltd, S-111, SIDCO Industrial Estate, Kakkalur-602003, Thiruvallur (Dist), Tamilnadu, India	Content of Methyl Salicylate and Menthol	Drugs Testing Laboratory, Madurai-19
70.	Telmisartan Tablets IP 40mg	TS24047	Oct-24	Dec-25	M/s. Eurokem Laboratories Pvt ltd, C-25, SIDCO Pharmaceutical Complex, Alathur, Thiruporur, 603110	Dissolution of Telmisartan Tablets	Drugs Testing Laboratory, Chennai-06.
71.	Telmisartan Tablets IP 40mg	TS24042	Oct-24	Dec-25	M/s. Eurokem Laboratories Pvt ltd, C-25, SIDCO Pharmaceutical Complex, Alathur, Thiruporur, 603110	Dissolution of Telmisartan Tablets	Drugs Testing Laboratory, Chennai-06.
72.	Olagress MD 2.5	D2250101	Jan-25	Dec-26	M/s.Standford Laboratories Private Limited, 8, Industrial Area, Mehatpur, Dist. Una, HP-174315 Mkted by: La renon Healthcare Private Limited, 207-208, Iscon Elegance, Prahlad, Nagar, Cross Road, SG Highway, Vejalpur, Ahmedabad, 380015, Guj.	The sample fails in the test for Description. Colour is not specified on the label.	Modern Drug Testing Laboratory Kathua (J&K)
73.	Olagress MD 5	D2241286	Dec-24	11/2026	M/s.Standford Laboratories Private Limited, 8, Industrial Area, Mehatpur, Dist. Una, HP-174315 Mkted by: La renon Healthcare Private Limited, 207-208, Iscon Elegance, Prahlad, Nagar, Cross Road, SG Highway, Vejalpur, Ahmedabad, 380015, Guj.	Description	Modern Drug Testing Laboratory Kathua (J&K)
74.	Pantoprazole Sodium IP Tablets 40mg (Lepan 40)	SPT-1134	Dec-24	Nov-26	M/s.Sheen Pharmaceuticals Wariana Industrial Complex-144021 Mkt by: Lebon Pharmaceuticals 603,G-I, Flaourite, Moraj Residency, Palm Beach, Vashi Mumbai-400705	Dissolution and Assay contents of Pantoprazole. Pantoprazole Sodium Tablets IP 40 mg is labelled as Pantoprazole Sodium IP Tablets 40 mg.	Modern Drug Testing Laboratory Kathua (J&K)
75.	Paracetamol Tablets IP (500mg) Jan Aushadhi	PCT1208	Aug-24	Jul-26	M/s.Unicure India Ltd, C-21, 22& 23, Sector-3, Noida-201301 Distt. Gautam Budh Nagar (UP). Mkt by: Pharmaceuticals and Medical	Dissolution test of paracetamol.	Modern Drug Testing Laboratory Kathua (J&K)

					Devices Bureau of India (PMBI) 8th Floor, Videocon Tower, Block E-1, Jhandewalan Extension, New Delhi-110055.		
76.	Paracetamol, Phenylphrine HCL, CPM & Caffeine Tablets (Goco-Plus)	DPT-1223	Sep-24	Aug-26	M/s. Dexibo Pharma Pvt. Ltd, Khasra No.: 3,4,5 and Part of 4M, Plot No. 134/2, Shiv Ganga Industrial Estate, Lakeshwari, Bhagwanpur, Distt. Haridwar-247 661 (U.K.)	Disintegration	State lab, Puducherry
77.	Rabeprazole Sodium Gastro Resistant Tablets IP 20mg (Rabilax)	MP-241462	Mar-25	Feb-27	M/s.Medistarkbiotech Pvt. Ltd., R.S.No. 68/4, 68/10, Sri Srinivasapuram, Agasampattu, Vanur Tk, Tamilnadu-605111	Disintegration.	State lab, Puducherry
78.	Ferrous Ascorbate, Folic Acid With Zinc Sulphate Tablets (Ronifer-XT)	24T374B	Feb-25	Jan-27	M/s. Acumen Pharmaceuticals Pvt. Ltd., RS-2, Plot No.117-118, Kurumbapet, Villianur Commune, Puducherry-605 009	Assay (Ferrous Ascorbate)	State lab, Puducherry
79.	Domperidone & Paracetamol Tablets (Coxnil-P)	FCPT-2401	Jun-24	May-26	M/s.Verax Life Sciences Pvt. Ltd., K.No. 436, Vill Suramara Badd, Dat. Solan (H.P) 173205	(i) On the received sample, Presence of Spot defect was observed	State lab, Puducherry
80.	Levocetirizine Tablets IP 5mg (Lzetri 5)	B2409435A	Sep-24	Aug-26	M/s Bymaa Laboratories Private Limited., A-19,20&22, Electronic Park,PIPDIC Industrial Estate, Thirubhuvanai , Puducherry - 605 107	For the received sample, label is mentioned as 'Approved colour used' but common name of the permitted colour used in the formulation	State lab, Puducherry
81.	Pantoprazole Sodium Gastro Resistant Tablets IP 40mg (Panzo 40)	MP-240840	Oct-24	Sep-26	M/s.Medistark Biotech Pvt Ltd., R.S.No. 68/4,68/10, Sri Srinivasapuram, Agasampattu, Vanur Tk,Tamilnadu - 605 111	For the received sample, label is mentioned as 'Approved colour used'	State lab, Puducherry
82.	Aceclofenac 100mg & Paracetamol 325 mg Tablets (Acejent P)	MVT-1528	Mar-25	Feb-27	M/s.Bonn Schtering Bio Sciences, Plot No.:64 & 65, 1 st Floor, Electronic Park, Thirubuvanai, Mannadipet Commune, Puducherry-605 107	The sample received is labelled as Aceclofenac 100mg & Paracetamol 325 mg Tablets (Acejent P), however Aceclofenac & Paracetamol Tablets is an official IP monograph (IP Addendum 2024) hence should be labelled as Aceclofenac & Paracetamol Tablets IP.	State lab, Puducherry
83.	Fluoxetine Capsules IP 20mg (Floxros-20 Capsules)	SC-24286	Dec-24	Nov-26	M/s.For Maxford Healthcare by Stafford Laboratories Pvt. Ltd.,	The label on the innermost container of the received Fluoxetine Capsules IP 20mg,sample does not	State lab, Puducherry

					143, Ranipur Ind. Area, Bhagwanpur, Roorkee, (UK)	mentioned the "Manufacturing Licence Number", which is required to be preceded by the words "Manufacturing Licence Number" or "Mfg.Lic.No" or "M.L"	
84.	Mintcool (mouthwash)	SOL-1698	Mar-24	Feb-26	M/s.Symbiosis Pharmaceuticals PvtLtd At .Ovatio Remedies Behind IITT Ergg Collage Trilokpur Road Kala Amb173030(sirmour)HP	Content of Chlorhexidine Gluconate .	DTL Baddi, Distt. Solan H.P.
85.	Cifdoz-500 (Ciprofloxacin Hydrochloride Tablets IP)	APGT24513	Jul-27	Jun-26	M/s.Alpex Pharma Pvt. Ltd. Vill. Ogli Suketi Road, Kala Amb Distt. Sirmour H.P.	Dissolution of Ciprofloxacin Hydrochloride	DTL Baddi, Distt. Solan H.P.
86.	Mecobalamin 2500mg. (NEROSAFE-XL)	324-80	Jul-24	May-26	Mft. by Not Mentioned Mkd. By M/s Safe Care Life Sciences, 3481.1, Ramtara Market, 2nd Floor, Gali Bajrang Bali, Chawri Bazar, Delhi, 110006.	Content of Mecobalamin found to be 2.38 mg per ml (0.095%) against labelled claim of 2500 mg per ml. 1) Manufacturing By not mentioned on the label.	State Drugs Laboratory, Punjab
87.	Calcium and Vitamin D3 Tablets IP	MT-25D59	Apr-25	Mar-27	M/s.Martin & brown bio-sciences pvt. Ltd, K.No.918/419, Malkumajra, Nalagarh Road, Baddi, Distt. Solan (H.P.)-173205	Description	State Drugs Laboratory, Punjab
88.	Zinc Sulphate Dispersible Tablets IP	MT14501	Apr-25	Mar-27	M/s. McW Healthcare (P) Ltd., 286 287A 287B Sector E Industrial Area Sanwer Road Indore 452015 (M.P.)	1. Uniformity Of Dispersion. 2. Disintegration Test (Some of the tablets disintegrates in the range of 4 minute to 7 minute against I.P limit of max. 60 seconds).	State Drugs Laboratory, Punjab
89.	Zinc Sulphate Dispersible Tablets IP (N/A)	MT14501	Apr-25	Mar-27	M/s. McW Healthcare (P) Ltd., 286, 287-A, 287-B Sector E, Industrial Area, Sanwer Road, Indore (M.P.) India	1.Disintegration Test (Some of the tablets disintegrated after 4 min against the IP limit of NMT 60 Seconds).Uniformity Of Dispersion	State Drugs Laboratory, Punjab
90.	TELMISARTAN and AMLODIPINE Tablets IP (Venpres-40 AM)	VAM401K	Nov-24	Oct-26	M/s.Leeford Healthcare Ltd. Plot No. 5, Apparel Park-cum- Industrial Area, Katha, Baddi, Distt. Solan 173205 (H.P), India	Description	State Drugs Laboratory, Punjab
91.	Calcium and Vitamin D3 Tablets IP	MT-25D60	Apr-25	Mar-27	M/s.Martin & brown bio-sciences pvt. Ltd, K.No.918/419,	Description	State Drugs Laboratory, Punjab

					Malkumajra, Nalagarh Road, Baddi, Distt. Solan (H.P.)-173205		
92.	Calcium and Vitamin D3 Tablets IP	MT-25D57	Apr-25	Mar-27	M/s.Martin & brown bio-sciences pvt. Ltd, K.No.918/419, Malkumajra, Nalagarh Road, Baddi, Distt. Solan (H.P.)-173205	Description	State Drugs Laboratory, Punjab
93.	Calcium and Vitamin D3 Tablets IP	MT-25D55	Apr-25	Mar-27	M/s.Martin & brown bio-sciences pvt. Ltd, K.No.918/419, Malkumajra, Nalagarh Road, Baddi, Distt. Solan (H.P.)-173205	Description	State Drugs Laboratory, Punjab
94.	Calcium and Vitamin D3 Tablets IP	MT-25D62	Apr-25	Mar-27	M/s.Martin & brown bio-sciences pvt. Ltd, K.No.918/419, Malkumajra, Nalagarh Road, Baddi, Distt. Solan (H.P.)-173205	Description	State Drugs Laboratory, Punjab
95.	Calcium and Vitamin D3 Tablets IP	MT-25D63	Apr-25	Mar-27	M/s.Martin & brown bio-sciences pvt. Ltd, K.No.918/419, Malkumajra, Nalagarh Road, Baddi, Distt. Solan (H.P.)-173205	Description	State Drugs Laboratory, Punjab
96.	Calcium and Vitamin D3 Tablets IP	MT-25D58	Apr-25	Mar-27	M/s.Martin & brown bio-sciences pvt. Ltd, K.No.918/419, Malkumajra, Nalagarh Road, Baddi, Distt. Solan (H.P.)-173205	Description	State Drugs Laboratory, Punjab
97.	Moxifloxacin 10% Injection (MOX-4TH GEN)	SL1220-21	Jan-24	Dec-26	Mft. by Not Mentioned Mkd. By M/s Safe Care Life Sciences, 3481.1, Ramtara Market, 2nd Floor, Gali Bajrang Bali, Chawri Bazar, Delhi, 110006.	Manufacturing By not mentioned on the label.	State Drugs Laboratory, Punjab
98.	Mecobalamin Tablets (Methycobal)	156905	Jan-25	Dec-27	M/s.Hilton Pharma (Pvt.) Ltd., Plot No. 13-14, Sector 15, Korangi Industrial Area, Karachi	Nature of Tablets Such as Uncoated, Sugar Coated or Film Coated not Declared on The Label	State Drugs Laboratory, Punjab
99.	Nortriptyline HCl B.P (Sensival 25MG Tablets)	926	Nov-24	Nov-27	M/s.Pharmedic Laboratories (Pvt.) Ltd., 16km, Multan Road, Lahore	1.) Name Of Colour Added Not Declared On The Strips. 2.) nature of tablets such as uncoated, sugar coated or film coated not declared on the strips.	State Drugs Laboratory, Punjab
100.	Mecobalamin (Neocobal 0.5mg Tablets)	7805	NM	Feb-26	M/s.Pulse Pharmaceuticals (Pvt.) Ltd., Sua Asil, Raiwind Road Lhore	1) Description. 2) Tablets Are Film Coated Against Labelled Claim of Sugar-Coated Tablets. 3) The Content of Methylcobalamin	State Drugs Laboratory, Punjab
101.	Calcium and Vitamin D3 Tablets IP	MT-25D72	Apr-25	Mar-27	M/s.Martin & Brown Bio-Sciences Pvt. Ltd., K.NO.918/419,	Description	State Drugs Laboratory, Punjab

					Malkumajra, Nalagarh Road, Baddi, Distt. Solan (H.P.)-173205		
102.	Calcium and Vitamin D3 Tablets IP	MT-25D74	Apr-25	Mar-27	M/s.Martin & Brown Bio-Sciences Pvt. Ltd., K.NO.918/419, Malkumajra, Nalagarh Road, Baddi, Distt. Solan (H.P.)-173205	Description	State Drugs Laboratory, Punjab
103.	Calcium and Vitamin D3 Tablets IP	MT-25D71	Apr-25	Mar-27	M/s.Martin & Brown Bio-Sciences Pvt. Ltd., K.NO.918/419, Malkumajra, Nalagarh Road, Baddi, Distt. Solan (H.P.)-173205	Description	State Drugs Laboratory, Punjab
104.	Calcium and Vitamin D3 Tablets IP	MT-25D82	Apr-25	Mar-27	M/s.Martin & Brown Bio-Sciences Pvt. Ltd., K.NO.918/419, Malkumajra, Nalagarh Road, Baddi, Distt. Solan (H.P.)-173205	Description	State Drugs Laboratory, Punjab
105.	Calcium and Vitamin D3 Tablets IP	MT-25D81	Apr-25	Mar-27	M/s.Martin & Brown Bio-Sciences Pvt. Ltd., K.NO.918/419, Malkumajra, Nalagarh Road, Baddi, Distt. Solan (H.P.)-173205	Description	State Drugs Laboratory, Punjab
106.	Oral Rehydration Salts IP	P25/0228	Jan-25	Apr-27	M/s.Samkem, 15-B, A.K.V.N. Industrial Area, Rangwasa, Rao, Indore-453331 (M.P.)	Net Weight/Sachet found to be 20.392gm against claim of 29.5gm/sachet.	State Drugs Laboratory, Punjab
107.	Oral Rehydration Salts IP	P25/0236	May-25	Apr-27	M/s.Samkem, 15-B, A.K.V.N. Industrial Area, Rangwasa, Rao, Indore-453331 (M.P.)	Net Weight/Sachet found to be 20.286gm against claim of 20.5gm/sachet.	State Drugs Laboratory, Punjab
108.	Calcium & Vitamin D3 Tablets I.P	MT-25D56	Apr-25	Mar-27	M/s.Martin & Brown Bio-Sciences Pvt. Ltd., K.NO.918/419, Malkumajra, Nalagarh Road, Baddi, Distt. Solan (H.P.)-173205	Description	State Drugs Laboratory, Punjab
109.	Calgro-D3 Tablets Calcium and Vitamin D3 tablets	AC.2412	Dec-24	May-26	M/s.Twins Pharma Plot No. 106, SV Nagar, Mallapur-76. Telangana	1. The label should be mentioned as Calcium And Vitamin D3 IP. But the letters IP is not mentioned after the product name. 2. Dissolution for Calcium.	State Lab, Drugs Control Laboratory, Telangana.
110.	Leofenac-TH4 Tablets Aceclofenac & Thiocolchicoside tabs	T25-054	Feb-25	Jan-27	M/s. Oaksun Lifesciences, Plot no. 36,37,38,46 & 47, Chengicherla (V), Medipally(M), Medchal-Malkajgiri (Dist.), T.S.-500092 Telangana	The drug failed to indicate the common name of the Colour used in the Drug on the product label.	State Lab, Drugs Control Laboratory, Telangana.
111.	PYRIL-650 Tablets Paracetamol Tablets IP 650 mg	T25.039	Feb-25	Jan-27	M/s. Oaksun Lifesciences, Plot no. 36,37,38,46 & 47, Chengicherla (V), Medipally(M), Medchal-Malkajgiri (Dist.), T.S.-500092 Telangana	The product Paracetamol Tablets is official in the current edition of the Indian Pharmacopoeia. However, the letters IP is	State Lab, Drugs Control Laboratory, Telangana.

						not mentioned on the product title.	
112.	VCEC-P Tablets Aceclofenac and Paracetamol Tablets	TG24-2028C	Sep-24	Aug-26	M/s Athens Life Sciences Mauza Rampur, Jattan, Nahan Road, Kala Amb, Distt. Sirmour, H.P.-173030	The label should be mentioned as Aceclofenac and Paracetamol IP. But the letter IP is not mentioned after the product name. Aceclofenac and Paracetamol	State Lab, Drugs Control Laboratory, Telangana.
113.	Tonzee-20 (Zinc Sulphate Tablets IP 20mg)	ZS-2405	Jul-24	Jun-26	M/s.Torino Laboratories Pvt. Ltd., Fact: Plot No. 65/1, Sector 1, Pithampur – 454775, Dist. Dhar (INDIA).	Disintegration	State Drugs Testing Laboratory, Agartala, Tripura.
114.	Azilium 200 Suspension	SL-508	Feb-24	Jan-26	M/s. SB Lifesciences (An ISO 9001:2015 Certified Co.) Plot no. 32, Sector-6, LLE Pantnagar, Distt. U.S. Nagar, Uttarakhand 263153	Content of Anhydrous Azithromycin	FDA Lab , Mumbai
115.	Azi. XL 200(Azithromycin Oral Suspension IP)	GLE0901	Aug-25	Jul-26	M/s. Digital Vision 176, Mauza Ogli, Nahan Road, Kala Amb, Dist. Sirmour (H.P) 173030	Content of Anhydrous Azithromycin	FDA Lab , Mumbai
116.	Osocip-D Eye/Ear drops Ciprofloxacin & Dexamethasone Eye/Ear drops IP	E240113A	Jan-24	Dec-25	M/s. Oscar Remedies Pvt Ltd., Oscar House, Badi Majra Yamuna Nagar 135001	Content of Ciprofloxacin in the sample is more (i.e 943.33% of the labelled amount) than the permissible limits. 2. identification test for the presence of Dexamethasone Sodium Phosphate. 3. The sample gives high performance liquid chromatographic identification test for the presence of Dexamethasone. 4. The content of Dexamethasone in the sample is 0.078% W/V. 5. Name of the sample: Ciprofloxacin & Dexamethasone Eye/Ear drops IP 2022.	FDA Lab , Mumbai
117.	Cetacin-150, Paracetamol Injection	TGL11230643	Nov-24	Oct-25	M/s. T & G Medicare Village Kunjahal, PO Baddi, Distt. Solan	50×2ml intact ambered coloured glass ampules received for the analysis. All the samples contain pink coloured solution.	FDA Lab , Mumbai

118.	P.D. Col Eye ointment IP 1% w/w	2023-113	Aug-23	Jul-25	M/s. Packsules 45, Keshar Bagh Road, Indore Madhya Pradesh- 452009	Uniformity of Weight.	FDA Lab , Mumbai
119.	Regimen Hand Rub Aloevera 70% Alcohol	HSAL0050	Oct-24	Oct-26	M/s. Chemstellar Chemicals Pvt Ltd. Plot No. 215, GR. Fl. Steel warehousing Comp. Kalamboli, Panvel, Raigad, Kalamboli-410208	1. The sample gives GC identification test for the presence of Methanol. 2. The sample does not give GC identification test for the presence of Ethanol, 1- Propanol & 2-Propanol. 3. The sample contains 51.80% v/v of Methanol.	FDA Lab , Mumbai
120.	Lycitra MK Montelukast with Levocetirizine Dihydrochloride Syrup	D-0241	Nov-23	Oct-25	M/s. Animus Healthcare30, Shubhlaxmi, Ind. Estate, Opp Sanket, Estate at Moraiya Ta: Sanand, Ahmedabad-3882213, Gujarat	The content of Montelukast (i.e 17.18% of the labelled amount) is less than the schedule V limit (Schedule V limit- 90%-110% of the labelled amount)	FDA Lab , Mumbai
121.	Oscorcip-D Eye/Ear Drops	E24020A	Feb-24	Jan-26	M/s. Oscar Remedies Pvt Ltd., Oscar House, Badi Majra Yamuna Nagar Haryana 135001	1. The content of Ciprofloxacin in the sample is more (i.e 1023.33% of the labelled amount) than the permissible limits. 2. The sample does not give HPLC identification test for the presence of Dexamethasone sodium phosphate. 3. The sample gives HPLC identification test for the presence of Dexamethasone. 4. The content of Dexamethasone in the sample is 0.066% w/v 5 . Test for the sterility.	FDA Lab , Mumbai
122.	Elcares Metronidazole 400(Metronidazole tablets IP 400 mg	MTE-22004	Feb-23	Jan-26	M/s. Neutech Healthcare private Ltd. E-698 ,DSIDC, Narela, Industrail, Delhi- 110040	Dissolution test.	FDA Lab , Mumbai
123.	Curacet Tablets (Cetirizine Hydrochloride)	CHT23320	Oct-23	Sep-25	M/s. Cureza Healthcare pvt. Ltd. A.B.Road Girwai, 474001	Almost all the tablets received for analysis show Grey coloured spots all over the surface of the tablet, when observed in	FDA Lab , Mumbai

						normal day light with unaided eyes.	
124.	Enrofloxacin Injection La (Welflox La)	VT240352A	Mar-24	Feb-26	M/s. Integrated Laboratories Pvt Ltd. Nahan Road, Vill. Muginand, Kala Amb, Distt. Sirmour Himachal Pradesh 173030	1. The Content of Enrofloxacin in the sample is less (i.e. 45.64% of the labelled amount)	FDA Lab , Mumbai
125.	Glavit Syrup 200ml	GLV-233	Apr-24	Sep-25	M/s. Glacier Pharmaceutical Pvt Ltd. G-5, MIDC, Industrial area Amaravati-444605	The content of Thiamine Hydrochloride(i.e. 63.8% of the labelled amount) and the content of Cyanocobalamin (i.e 13.34% of the labelled amount) in the sample are less than the permissible limit.	FDA Lab , Mumbai
126.	Glavit Syrup100ml	GLV-230	Mar-24	Aug-25	M/s. Glacier Pharmaceutical Pvt Ltd. G-5, MIDC, Industrial area Amaravati-444605	The content of Thiamine Hydrochloride(i.e. 74.7% of the labelled amount) and the content of Cyanocobalamin (i.e 11.92% of the labelled amount) in the sample are less than the permissible limit.	FDA Lab , Mumbai
127.	Elzefen-P (Aceclofenac & Paracetamol Tablets)	PC24021	Mar-2024	Feb-2026	M/s Prochem Pharmaceuticals Pvt., Ltd., 140-141, Makkanpur, Bhagwanpur, Roorkee, Distt.- Haridwar,(Uttarakhand)-247661	Assay of Aceclofenac	Central Drugs Laboratory, 3, Kyd Street, Kolkata-700016
128.	Onvin-4 MD Tablets (Ondansetron Orally Disintegrating Tablets IP 4 mg)	RV24012	May-2024	Apr--2026	M/s Rivpra Formulation Pvt., Ltd., Plot No.8, Sector-6A, IIE, SIDCUL, Haridwar-249403	Test for Related Substances	Central Drugs Laboratory, 3, Kyd Street, Kolkata-700016
129.	EBD ORS(Oral Rehydration Salts IP)	825220	02/2025	01/2027	Mfg. by- M/s Syndicate Pharma, 185/B-1, 187/A & 188, Sector F, Sanwer Road, Industrial Area, Indore(M.P.)-452015, Mkt. by M/s Elder Bio Drugs Pvt. Ltd., Plot No. 15/1, Pipliya Kumar, 1B-1st Floor, 37-A, Mangal Compound, Dewas Naka, Lasudia Mori, Pincode-452010	Uniformity of weight	State Drug Testing Laboratory, Jharkhand
130.	ORS(Oral Rehydration Salts IP)	P0831	04/2024	03/2026	M/s Quest Laboratories Limited, Plot No. 45, Sector-III, Pithampur, Dist.- Dhar-454775(M.P.)	Uniformity of weight	State Drug Testing Laboratory, Jharkhand

Not of Standard Quality (NSQ) drugs:

The drugs that fail to meet the quality standards or specifications are known as Not of Standard Quality (NSQ) drugs.

(Further, the term 'standards of quality' is defined under the Section 16 (1) (a) of Drugs & Cosmetics Act, 1940, that the 'standards of quality' mean that the drug complies with the standards set out in the Second Schedule of the said Act.)

NOTE:

1. NSQ data received from State Drugs Licensing Authorities of **Himachal Pradesh, Jharkhand, Karnataka, Maharashtra, Punjab, Tamilnadu, Telangana, Tripura, West Bengal(Nil), Puducherry, Jammu & Kashmir, Ladakh (Nil)**, for the month of June, 2025 as per DCG (I) Circular dated 09.02.2024.
2. State Drugs Licensing Authorities of Andhra Pradesh, Arunachal Pradesh, Assam, Bihar, Chhattisgarh, Goa, Gujarat, Haryana, Kerala, Madhya Pradesh, Manipur, Meghalaya, Mizoram, Nagaland, Odisha, Rajasthan, Sikkim, Uttar Pradesh, Uttarakhand, Andaman & Nicobar Islands, Chandigarh, Dadar and Nagar Haveli, Daman and Diu, Delhi, Lakshadweep have not submitted any data in respect of the Not of Standard Quality (NSQ) Alert for the Month of June, 2025 as per DCG(I) Circular dated 09.02.2024.

Annexure C

ALL INDIA INSTITUTE OF MEDICAL SCIENCES
ANSARI NAGAR, NEW DELHI – 110029
HOSPITAL STORES

NOTICE OF TERMINATION OF CONTRACT AND DEBARMENT

F. NO. 11A/H/Drugs/2022-23

Dated: 27th September, 2025

To,

M/s Pentagon Labs Limited,
206, Archana Apartment 8-B
Ratlam Kothi, Inddore – 452001
E-mail: pentagonlabsltd@yahoo.co.in

Subject: Rate Contract No. 11A/H/Drugs/2022-23 dated 07.05.2024 in favor of M/s Pentagon Labs Limited for providing Crystalloid Supplies to AIIMS, New Delhi – Termination of contract and debarment/ blacklisted for two years from participating in tenders thereof.

References:

- 1) Rate Contract No. 11A/H/Drugs/2022-23 dated 07.05.2024
- 2) Complaint letter dated 28.06.2025 regarding Fungus found in Inj. Mannitol (Batch No. 24GMN014)
- 3) Complaint letter dated 04.07.2025 to M/s Pentagon Labs Limited
- 4) Another letter dated 08.07.2025 to M/s Pentagon Labs Limited
- 5) First Personal Hearing Meeting dated. 09.07.2025
- 6) Second Personal Hearing Meeting dated. 05.08.2025 and information regarding contamination in IV fluid products supplied by M/s Pentagon Labs Limited in the crystalloid products
- 7) Show Cause Notice dated 12.09.2025
- 8) Response letters dated 13.09.2025 and 15.09.2025 from M/s Pentagon Labs Limited

Whereas:

1. AIIMS, New Delhi, placed a rate contract vide no. 11A/H/Drugs/2022-23 dated 07.05.2024 with M/s Pentagon Labs Limited for providing Crystalloid Supplies at AIIMS, New Delhi. This contract was valid for a two-year term from 07.05.2024 to 06.05.2026.
2. During the contract execution period, complaints were received from user-departments regarding Fungus found in Inj. Mannitol (Batch No. 24GMN014).
3. In view of the non-compliance with the contract requirements, a complaint letter dated 04.07.2025 was issued to M/s Pentagon Labs Limited to give an opportunity to the vendor

to improve and with instructions to replace 4800 bottles of Inj. Mannitol, supplied under Batch No. 24GMN014, within a week.

4. Neither the said batch was replaced nor any response was received from M/s Pentagon Labs Limited which in violation of Clause 5.5 of Section IV (General Conditions of Contract) of Tender No. 11A/H/Drugs/2022-23, liable to be debarred and this non-compliance was taken very seriously by the competent authority in view of the safety of the patients at AIIMS.
5. Another letter dated 08.07.2025 was issued to M/s Pentagon Labs Limited with instruction to attend a personal hearing meeting on 09.07.2025 to explain the reason for this gross non-compliance which can put serious risk to patient care services.
6. In the personal hearing meeting held on 09.07.2025, Mr. Ashwani Kumar, the representative of M/s Pentagon Labs Limited who attended the meeting was informed about the serious concerns over the repeated trend of contamination found in the injectable products supplied, posing serious risk to patient safety and undermines public trust in the healthcare system.
7. In the meeting, Mr. Ashwani Kumar, the representative of M/s Pentagon Labs Limited acknowledged the issue and suggested that the contamination could have occurred due to issues during transportation or storage. He further stated that, as per Pharmacopeia standards, FDA guidelines and other Govt. Of India instructions, a certain minimal percentage of such defects is considered permissible. He added that instructions are clearly printed on each label, advising the user to check the product before use.
8. The representative of M/s Pentagon Labs Limited was informed that such incidents of contamination have significantly increased in recent times, which was not observed earlier and expressed serious concern over this emerging trend. In the meeting it was emphasized that even a single contaminated bottle in a sterile injectable product is a matter of grave concern and is a criminal offence, especially in a critical healthcare setting like AIIMS and is not acceptable.
9. In spite of our letters dated 04.07.2025 & 08.07.2025, no action was taken by the vendor to replace the 4800 bottles of Inj. Mannitol, supplied under Batch No. 24GMN014, within a week. This shows non-ethical and irresponsible attitude on part of M/s Pentagon Labs Limited.
10. In view of non-compliance and negligence on the part of the firm and to ensure uninterrupted services in the best interest of patients at AIIMS, AIIMS was compelled to do risk purchase from open market under the provisions of Clause 5.5(f) of Section IV (General Conditions of Contract) of Tender No. 11A/H/Drugs/2022-23 to run the patient

care services smoothly despite having a rate contract and affected the functioning, put extra burden and reduced efficiency of the procurement system apart from problems in the user areas.

11. Subsequently, in view of the contamination of Mannitol, other batches of crystalloid supplies made by M/s Pentagon Labs Limited were tested in the Microbiology Laboratory of the Institute under the provisions of Clause 5.1 of Section IV (General Conditions of Contract) of Tender No. 11A/H/Drugs/2022-23 and as per the test Report dated 23.07.2025, formation of fungus was found in the following crystalloid preparations manufactured and supplied by M/s Pentagon Labs Limited:

Sl. No.	Name of Item	Supply Order No. and Date	Batch No.
1	DNS (Dex. + Sod. Chloride) 5 gm + 0.9 gm/100 ml (500ml)	2324/H/CSK/24-25 dated 27.09.2024	24GB061
2	5% Dextrose 500ml	2894/H/CSK/24-25 dated 11.11.2024	24GA035 & 25GA002
3	20% Mannitol 100ml	2422/H/CSK/24-25 dated 18.10.2025	24GMN014
4	50% Dextrose 100ml	2807/H/CSK/24-25 dated 25.10.2024	24GAD003

12. From the above; it is evident that in spite of given the opportunities to improve including personal hearing, the crystalloid supplies made by M/s Pentagon Labs Limited to AIIMS, New Delhi have been found to be of sub-standard quality with no improvisation. This continued gross misconduct and safety issues were taken very seriously by the competent authority at AIIMS, New Delhi.

13. Second personal hearing meeting was held on 05.08.2025 wherein Mr. Rajesh Sinha; the representative of M/s Pentagon Labs Limited attended the meeting. During the deliberations, it was strictly conveyed to the representative of M/s Pentagon Labs Limited of repeated complaints of fungus contamination in IV fluid products supplied by M/s Pentagon Labs Limited in the following crystalloid products:

Sl. No.	Name of Item	Supply Order No. and Date	Batch No.
1	DNS (Dex. + Sod. Chloride) 5 gm + 0.9 gm/100 ml (500ml)	2324/H/CSK/24-25 dated 27.09.2024	24GB061
2	5% Dextrose 500ml	2894/H/CSK/24-25 dated 11.11.2024	24GA035 & 25GA002
3	20% Mannitol 100ml	2422/H/CSK/24-25 dated 18.10.2025	24GMN014
4	50% Dextrose 100ml	2807/H/CSK/24-25 dated 25.10.2024	24GAD003

14. During the meeting, it was conveyed to the representative of M/s Pentagon Labs Limited that in the previous personal hearing meeting held on 09.07.2025 the matter of fungal growth in Mannitol 20% 100 ml glass bottle was raised, however, no effective corrective actions were implemented by the vendor following the meeting.
15. The representative of M/s Pentagon Labs Limited, **acknowledged the multiple complaints and confirmed that more than 3 instances have been reported regarding visible fungal growth in the sealed IV fluids glass bottles supplied.** The representative of M/s Pentagon Labs Limited admitted the possibility of glass quality issues. He further acknowledged that on receipt of complaint of fungus found in the bottles, some improvements have been made in manufacturing, including changing the bottle cock.
16. During the meeting, it was observed and documented that fungal growth was found in many samples of the products manufactured by M/s Pentagon Labs Limited.
17. Representative of M/s Pentagon Labs Limited indicated that the company will investigate potential faults in third party supplied components such as glass bottles and caps.
18. During the meeting, it was made clear that M/s Pentagon Labs Limited is solely responsible for ensuring product quality and compliance, regardless of third party involvement. It was also noted that the defective batch of Mannitol 20% 100 ml glass bottle has not been fully replaced, despite repeated reminders.
19. This response of the representative of M/s Pentagon Labs Limited in the meeting was found unsatisfactory and unacceptable, since such incidents can occur in the future also and can put serious risk to patient care services, hence is unacceptable. Therefore it was recommended to initiate process to debar Ms Pentagon Labs Limited for a period of two (02) years and it was further recommended that the matter will be documented and formally escalated to regulatory authorities for further investigation and appropriate action.
20. The vendor was thereafter issued a Show Cause Notice dated 12.09.2025 asking why contractual and safety provisions should not be enforced, including termination and debarment.
21. In its reply dated 13.09.2025, M/s Pentagon Labs Limited expressed regret and proposed replacement of defective batches, citing compliance with labeling requirements and manufacturing processes, but failed to adequately address repeated lapses and the risks posed to patient safety. They submitted that, *"as regards the quality of products supplied is concerned, glass bottles quite often get cracks developed upon mishandling or improper storage, and fungus may develop in those affected bottles only. However, we are not taking any excuse to escape from our responsibility of manufacturing, distributing*

and supplying 'STANDARD QUALITY DRUGS' to serve the noble profession of Health Care" and assured that "ENTIRE SUPPLIED QUANTITY OF AFFECTED DRUG AND NOW IT WILL BE REPLACED WITH FRESH STOCKS OF THE ANOTHER BATCH OF DRUG" and further requested not to initiate any further action in this matter.

22. In another reply dated 15.09.2025, M/s Pentagon Labs Limited further submitted that:
- a. We are providing information on the label of the Particular Drugs as prescribed by the individual monographs in Indian Pharmacopeia which is mandatory to us as per the Drugs and Cosmetic Acts 1940 and Rules Made their under.
 - b. The Product Mannitol Injection IP monograph requires Labelling Information regarding labeling is that: "**the Injection should not be used if it contains visible solid particles which do not dissolved on warming**".
 - c. Mannitol Injection is a life savings Drugs and as being Glass container it requires to be handle with care in all stages including transportation, storage, shifting and before its final uses. Hence we have mention Caution in red color as under:
CAUTION: Examine the bottle before use and do not use if the solution is found leaking or having particulate matter & fungal contamination which may occur due to even invisible damage to bottle in transit or storage or vacuum lost
And further requested not to initiate any further action in this matter against.
23. The competent authority at AIIMS reviewed all documents, responses, hearings, and applicable rules. It was observed that despite ample opportunity and warnings, the vendor failed to adhere to contractual provisions, resulting in a risk to patient safety, disruptions in medical services, and erosion of public trust.
24. The persistent failure of M/s Pentagon Labs Limited to improve and adhere to the contractual provisions coupled with repeated instances of unethical conduct even after given the opportunity the act of M/s Pentagon Labs Limited is considered as violations of Clause 5.5 of Section IV (General Conditions of Contract) of Tender No. 11A/H/Drugs/2022-23 which stipulates that,
- "If any drug sample fails the test or is found to be of substandard quality, action as below will be initiated:*
- (a) If any store/stores supplied against the contract are found to be not of standard quality as per specifications on analysis and/or on inspection by competent authority, the Institute will destroy the entire consignment against the particular invoice, irrespective of fact that part of the supplied stores may have been consumed. The institute shall not be liable to make any payments in lieu of inferior items.*
 - (b) If the firm fails to make fresh supplies in lieu of substandard quality of drug, it is liable to be debarred for three years in respect of all the items in the rate-contract of this Institute and EMD/Performance security shall be forfeited.*
 - (c) If the product is found to be not of standard quality, the cost of testing done by the Institute will be recovered from the supplier.*

(d) In case, the supplies are found to be of inferior quality on three occasions, the firm shall be liable for debarment for subsequent tender of Drugs and EMD/Performance security shall be forfeited.

(e) A copy of the test report will be sent to the DCGI for necessary action at their end.

(f) If any drugs supplied against this Rate Contract are found to be not of standard quality on inspection by Competent Authority, the pharmaceutical firm will be liable to replace the entire quantity within 15 days otherwise risk purchase will be charged from the company and the cost of testing will be recovered from the supplier."

25. The violations of contractual obligations by M/s Pentagon Labs Limited lead to the competent authority at AIIMS, New Delhi to view these matters with utmost seriousness and decided to debar M/s Pentagon Labs Limited for the following items for 02 years as per Clause 5.5 (a), (b), (d), (e) of Section IV (General Conditions of Contract) of Tender No. 11A/H/Drugs/2022-23 and under the provisions of Clause 5 (C) of O.M. F.1/20/2018-PPD dated 02.11.2021 issued by Procurement Policy Division, Deptt. of Expenditure, Ministry of Finance, Govt. of India:

Sl. No.	Name of Item
1	DNS (Dex. + Sod. Chloride) 5 gm + 0.9 gm/100 ml (500ml)
2	5% Dextrose 500ml
3	20% Mannitol 100ml
4	50% Dextrose 100ml

In light of these findings and the fact that despite ample opportunity and warnings, the vendor failed to adhere to contractual provisions, resulting in a risk to patient safety, disruptions in medical services, and erosion of public trust; following actions are hereby ordered:

a) Termination of the existing contract for following 04 items due to repeated supply of sub-standard quality of crystalloid supplies under the provisions of Clause 12.1 of Section IV (General Conditions of Contract) of Tender No. 11A/H/Drugs/2022-23:

Sl. No.	Name of Item
1	DNS (Dex. + Sod. Chloride) 5 gm + 0.9 gm/100 ml (500ml)
2	5% Dextrose 500ml
3	20% Mannitol 100ml
4	50% Dextrose 100ml

b) The due payment against the above-mentioned batches of crystalloid items shall be withheld under the provisions of Clause 5.5(a) of Section IV (General Conditions of Contract) of Tender No. 11A/H/Drugs/2022-23

c) A letter along with copies of the test report will be sent to the DCGI for necessary action at their end under the provisions of Clause 5.5(e) of Section IV (General Conditions of Contract) of Tender No. 11A/H/Drugs/2022-23

- d) M/s Pentagon Labs Limited is debarred from participating in AIIMS tenders and contracts for 02 years with immediate effect under the provisions of Clause 5.5(b), 5.5 (d) of Section IV (General Conditions of Contract) of Tender No. 11A/H/Drugs/2022-23 and under the provisions of Clause 5 (C) of O.M. F.1/20/2018-PPD dated 02.11.2021 issued by Procurement Policy Division, Deptt. of Expenditure, Ministry of Finance, Govt. of India.
- e) In case contamination is found in other crystalloid products under the above mentioned rate contract, the Performance Bank Guarantee (PBG) submitted by M/s Pentagon Labs Limited will be forfeited.

This order is being issued after considering all facts, documents, hearings, and applicable rules. The decision is based on the repeated supply of sub-standard quality products that compromise patient safety and violate contractual obligations, as detailed above.

This issues with the approval of the Competent Authority.


27/9/25
Medical

Superintendent
Main Hospital, AIIMS,
(For and on behalf of
the Director, AIIMS,
New Delhi)

Medical Superintendent
A.I.I.M.S. Hospital
New Delhi-110029

Copy to:

1. PPS to Director, AIIMS, New Delhi
2. PS to Addl. Director (Admin), AIIMS, New Delhi
3. PS to Sr. Financial Advisor, AIIMS, New Delhi
4. All Chief of Centers, AIIMS, New Delhi
5. All Senior Stores Officer/ Store Officer/ Assistant Store Officer, AIIMS, New Delhi
6. Stores Accounts Section, AIIMS, New Delhi
7. Professor In-Charge, Computer Facility: with request to upload the order on AIIMS website.

Email

SATISH SANGAWAT

Rate Contract No. 11A/H/Drugs/2022-23 dated 07.05.2024 in favor of M/s Pentagon Labs Limited for providing Crystalloid Supplies to AIIMS, New Delhi - Termination of contract and debarment/ blacklisted for two years from participating in tenders thereof

From : SATISH SANGAWAT <ssangawat@aiims.gov.in> Sat, Sep 27, 2025 12:15 PM
Subject : Rate Contract No. 11A/H/Drugs/2022-23 dated 07.05.2024 in favor of M/s Pentagon Labs Limited for providing Crystalloid Supplies to AIIMS, New Delhi - Termination of contract and debarment/ blacklisted for two years from participating in tenders thereof 1 attachment
To : pentagonlabsltd@yahoo.co.in

ALL INDIA INSTITUTE OF MEDICAL SCIENCES
ANSARI NAGAR, NEW DELHI – 110029
HOSPITAL STORES

NOTICE OF TERMINATION OF CONTRACT AND DEBARMENT

F. NO. 11A/H/Drugs/2022-23
2025

Dated: 27th September,

To,

M/s Pentagon Labs Limited,
206, Archana Apartment 8-B
Ratlam Kothi, Inddore – 452001
E-mail: pentagonlabsltd@yahoo.co.in

Subject: Rate Contract No. 11A/H/Drugs/2022-23 dated 07.05.2024 in favor of M/s Pentagon Labs Limited for providing Crystalloid Supplies to AIIMS, New Delhi - Termination of contract and debarment/ blacklisted for two years from participating in tenders thereof.

References:

- 1) Rate Contract No. 11A/H/Drugs/2022-23 dated 07.05.2024
- 2) Complaint letter dated 28.06.2025 regarding Fungus found in Inj. Mannitol (Batch No. 24GMN014)
- 3) Complaint letter dated 04.07.2025 to M/s Pentagon Labs Limited
- 4) Another letter dated 08.07.2025 to M/s Pentagon Labs Limited
- 5) First Personal Hearing Meeting dated. 09.07.2025
- 6) Second Personal Hearing Meeting dated. 05.08.2025 and information regarding contamination in IV fluid products supplied by M/s Pentagon Labs Limited in the crystalloid products
- 7) Show Cause Notice dated 12.09.2025
- 8) Response letters dated 13.09.2025 and 15.09.2025 from M/s Pentagon Labs Limited

Whereas:

1. AIIMS, New Delhi, placed a rate contract vide no. 11A/H/Drugs/2022-23 dated 07.05.2024 with M/s Pentagon Labs Limited for providing Crystalloid Supplies at AIIMS, New Delhi. This contract was valid for a two-year term from 07.05.2024 to 06.05.2026.
2. During the contract execution period, complaints were received from user-departments regarding Fungus found in Inj. Mannitol (Batch No. 24GMN014).
3. In view of the non-compliance with the contract requirements, a complaint letter dated 04.07.2025 was issued to M/s Pentagon Labs Limited to give an opportunity to the vendor to improve and with

- instructions to replace 4800 bottles of Inj. Mannitol, supplied under Batch No. 24GMN014, within a week.
4. Neither the said batch was replaced nor any response was received from M/s Pentagon Labs Limited which in violation of Clause 5.5 of Section IV (General Conditions of Contract) of Tender No. 11A/H/Drugs/2022-23, liable to be debarred and this non-compliance was taken very seriously by the competent authority in view of the safety of the patients at AIIMS.
 5. Another letter dated 08.07.2025 was issued to M/s Pentagon Labs Limited with instruction to attend a personal hearing meeting on 09.07.2025 to explain the reason for this gross non-compliance which can put serious risk to patient care services.
 6. In the personal hearing meeting held on 09.07.2025, Mr. Ashwani Kumar, the representative of M/s Pentagon Labs Limited who attended the meeting was informed about the serious concerns over the repeated trend of contamination found in the injectable products supplied, posing serious risk to patient safety and undermines public trust in the healthcare system.
 7. In the meeting, Mr. Ashwani Kumar, the representative of M/s Pentagon Labs Limited acknowledged the issue and suggested that the contamination could have occurred due to issues during transportation or storage. He further stated that, as per Pharmacopeia standards, FDA guidelines and other Govt. Of India instructions, a certain minimal percentage of such defects is considered permissible. He added that instructions are clearly printed on each label, advising the user to check the product before use.
 8. The representative of M/s Pentagon Labs Limited was informed that such incidents of contamination have significantly increased in recent times, which was not observed earlier and expressed serious concern over this emerging trend. In the meeting it was emphasized that even a single contaminated bottle in a sterile injectable product is a matter of grave concern and is a criminal offence, especially in a critical healthcare setting like AIIMS and is not acceptable.
 9. In spite of our letters dated 04.07.2025 & 08.07.2025, no action was taken by the vendor to replace the 4800 bottles of Inj. Mannitol, supplied under Batch No. 24GMN014, within a week. This shows non-ethical and irresponsible attitude on part of M/s Pentagon Labs Limited.
 10. In view of non-compliance and negligence on the part of the firm and to ensure uninterrupted services in the best interest of patients at AIIMS, AIIMS was compelled to do risk purchase from open market under the provisions of Clause 5.5(f) of Section IV (General Conditions of Contract) of Tender No. 11A/H/Drugs/2022-23 to run the patient care services smoothly despite having a rate contract and affected the functioning, put extra burden and reduced efficiency of the procurement system apart from problems in the user areas.
 11. Subsequently, in view of the contamination of Mannitol, other batches of crystalloid supplies made by M/s Pentagon Labs Limited were tested in the Microbiology Laboratory of the Institute under the provisions of Clause 5.1 of Section IV (General Conditions of Contract) of Tender No. 11A/H/Drugs/2022-23 and as per the test Report dated 23.07.2025, formation of fungus was found in the following crystalloid preparations manufactured and supplied by M/s Pentagon Labs Limited:

Sl. No.	Name of Item	Supply Order No. and Date	Batch No.
1	DNS (Dex. + Sod. Chloride) 5 gm + 0.9 gm/100 ml (500ml)	2324/H/CSK/24-25 dated 27.09.2024	24GB061
2	5% Dextrose 500ml	2894/H/CSK/24-25 dated 11.11.2024	24GA035 & 25GA002
3	20% Mannitol 100ml	2422/H/CSK/24-25 dated 18.10.2025	24GMN014
4	50% Dextrose 100ml	2807/H/CSK/24-25 dated 25.10.2024	24GAD003

12. From the above; it is evident that in spite of given the opportunities to improve including personal hearing, the crystalloid supplies made by M/s Pentagon Labs Limited to AIIMS, New Delhi have been found to be of sub-standard quality with no improvisation. This continued gross misconduct and safety issues were taken very seriously by the competent authority at AIIMS, New Delhi.

13. Second personal hearing meeting was held on 05.08.2025 wherein Mr. Rajesh Sinha; the representative of M/s Pentagon Labs Limited attended the meeting. During the deliberations, it was strictly conveyed to the representative of M/s Pentagon Labs Limited of repeated complaints of fungus contamination in IV fluid products supplied by M/s Pentagon Labs Limited in the following crystalloid products:

Sl. No.	Name of Item	Supply Order No. and Date	Batch No.
1	DNS (Dex. + Sod. Chloride) 5 gm + 0.9 gm/100 ml (500ml)	2324/H/CSK/24-25 dated 27.09.2024	24GB061
2	5% Dextrose 500ml	2894/H/CSK/24-25 dated 11.11.2024	24GA035 & 25GA002
3	20% Mannitol 100ml	2422/H/CSK/24-25 dated 18.10.2025	24GMN014
4	50% Dextrose 100ml	2807/H/CSK/24-25 dated 25.10.2024	24GAD003

14. During the meeting, it was conveyed to the representative of M/s Pentagon Labs Limited that in the previous personal hearing meeting held on 09.07.2025 the matter of fungal growth in Mannitol 20% 100 ml glass bottle was raised, however, no effective corrective actions were implemented by the vendor following the meeting.
15. The representative of M/s Pentagon Labs Limited, **acknowledged the multiple complaints and confirmed that more than 3 instances have been reported regarding visible fungal growth in the sealed IV fluids glass bottles supplied.** The representative of M/s Pentagon Labs Limited admitted the possibility of glass quality issues. He further acknowledged that on receipt of complaint of fungus found in the bottles, some improvements have been made in manufacturing, including changing the bottle cock.
16. During the meeting, it was observed and documented that fungal growth was found in many samples of the products manufactured by M/s Pentagon Labs Limited.
17. Representative of M/s Pentagon Labs Limited indicated that the company will investigate potential faults in third party supplied components such as glass bottles and caps.
18. During the meeting, it was made clear that M/s Pentagon Labs Limited is solely responsible for ensuring product quality and compliance, regardless of third party involvement. It was also noted that the defective batch of Mannitol 20% 100 ml glass bottle has not been fully replaced, despite repeated reminders.
19. This response of the representative of M/s Pentagon Labs Limited in the meeting was found unsatisfactory and unacceptable, since such incidents can occur in the future also and can put serious risk to patient care services, hence is unacceptable. Therefore it was recommended to initiate process to debar Ms Pentagon Labs Limited for a period of two (02) years and it was further recommended that the matter will be documented and formally escalated to regulatory authorities for further investigation and appropriate action.
20. The vendor was thereafter issued a Show Cause Notice dated 12.09.2025 asking why contractual and safety provisions should not be enforced, including termination and debarment.
21. In its reply dated 13.09.2025, M/s Pentagon Labs Limited expressed regret and proposed replacement of defective batches, citing compliance with labeling requirements and manufacturing processes, but failed to adequately address repeated lapses and the risks posed to patient safety. They submitted that, ***"as regards the quality of products supplied is concerned, glass bottles quite often get cracks developed upon mishandling or improper storage, and fungus may develop in those affected bottles only. However, we are not taking any excuse to escape from our responsibility of manufacturing, distributing and supplying 'STANDARD QUALITY DRUGS' to serve the noble profession of Health Care"*** and assured that ***"ENTIRE SUPPLIED QUANTITY OF AFFECTED DRUG AND NOW IT WILL BE REPLACED WITH FRESH STOCKS OF THE ANOTHER BATCH OF DRUG"*** and further requested not to initiate any further action in this matter.

22. In another reply dated 15.09.2025, M/s Pentagon Labs Limited further submitted that:
- We are providing information on the label of the Particular Drugs as prescribed by the individual monographs in Indian Pharmacopeia which is mandatory to us as per the Drugs and Cosmetic Acts 1940 and Rules Made their under.
 - The Product Mannitol Injection IP monograph requires Labelling Information regarding labeling is that: **"the Injection should not be used if it contains visible solid particles which do not dissolved on warming"**.
 - Mannitol Injection is a life savings Drugs and as being Glass container it requires to be handle with care in all stages including transportation, storage, shifting and before its final uses. Hence we have mention Caution in red color as under:
CAUTION: Examine the bottle before use and do not use if the solution is found leaking or having particulate matter & fungal contamination which may occur due to even invisible damage to bottle in transit or storage or vacuum lost
And further requested not to initiate any further action in this matter against.
23. The competent authority at AIIMS reviewed all documents, responses, hearings, and applicable rules. It was observed that despite ample opportunity and warnings, the vendor failed to adhere to contractual provisions, resulting in a risk to patient safety, disruptions in medical services, and erosion of public trust.
24. The persistent failure of M/s Pentagon Labs Limited to improve and adhere to the contractual provisions coupled with repeated instances of unethical conduct even after given the opportunity the act of M/s Pentagon Labs Limited is considered as violations of Clause 5.5 of Section IV (General Conditions of Contract) of Tender No. 11A/H/Drugs/2022-23 which stipulates that,
"If any drug sample fails the test or is found to be of substandard quality, action as below will be initiated:
- If any store/stores supplied against the contract are found to be not of standard quality as per specifications on analysis and/or on inspection by competent authority, the Institute will destroy the entire consignment against the particular invoice, irrespective of fact that part of the supplied stores may have been consumed. The institute shall not be liable to make any payments in lieu of inferior items.*
 - If the firm fails to make fresh supplies in lieu of substandard quality of drug, it is liable to be debarred for three years in respect of all the items in the rate-contract of this Institute and EMD/Performance security shall be forfeited.*
 - If the product is found to be not of standard quality, the cost of testing done by the Institute will be recovered from the supplier.*
 - In case, the supplies are found to be of inferior quality on three occasions, the firm shall be liable for debarment for subsequent tender of Drugs and EMD/Performance security shall be forfeited.*
 - A copy of the test report will be sent to the DCGI for necessary action at their end.*
 - If any drugs supplied against this Rate Contract are found to be not of standard quality on inspection by Competent Authority, the pharmaceutical firm will be liable to replace the entire quantity within 15 days otherwise risk purchase will be charged from the company and the cost of testing will be recovered from the supplier."*
25. The violations of contractual obligations by M/s Pentagon Labs Limited lead to the competent authority at AIIMS, New Delhi to view these matters with utmost seriousness and decided to debar M/s Pentagon Labs Limited for the following items for 02 years as per Clause 5.5 (a), (b), (d), (e) of Section IV (General Conditions of Contract) of Tender No. 11A/H/Drugs/2022-23 and under the provisions of Clause 5 (C) of O.M. F.1/20/2018-PPD dated 02.11.2021 issued by Procurement Policy Division, Deptt. of Expenditure, Ministry of Finance, Govt. of India:

Sl. No.	Name of Item
1	DNS (Dex. + Sod. Chloride) 5 gm + 0.9 gm/100 ml (500ml)
2	5% Dextrose 500ml
3	20% Mannitol 100ml
4	50% Dextrose 100ml

In light of these findings and the fact that despite ample opportunity and warnings, the vendor failed to adhere to contractual provisions, resulting in a risk to patient safety, disruptions in medical services, and erosion of public trust; following actions are hereby ordered:

- a) Termination of the existing contract for following 04 items due to repeated supply of sub-standard quality of crystalloid supplies under the provisions of Clause 12.1 of Section IV (General Conditions of Contract) of Tender No. 11A/H/Drugs/2022-23:

Sl. No.	Name of Item
1	DNS (Dex. + Sod. Chloride) 5 gm + 0.9 gm/100 ml (500ml)
2	5% Dextrose 500ml
3	20% Mannitol 100ml
4	50% Dextrose 100ml

- b) The due payment against the above-mentioned batches of crystalloid items shall be withheld under the provisions of Clause 5.5(a) of Section IV (General Conditions of Contract) of Tender No. 11A/H/Drugs/2022-23
- c) A letter along with copies of the test report will be sent to the DCGI for necessary action at their end under the provisions of Clause 5.5(e) of Section IV (General Conditions of Contract) of Tender No. 11A/H/Drugs/2022-23
- d) M/s Pentagon Labs Limited is debarred from participating in AIIMS tenders and contracts for 02 years with immediate effect under the provisions of Clause 5.5(b), 5.5 (d) of Section IV (General Conditions of Contract) of Tender No. 11A/H/Drugs/2022-23 and under the provisions of Clause 5 (C) of O.M. F.1/20/2018-PPD dated 02.11.2021 issued by Procurement Policy Division, Deptt. of Expenditure, Ministry of Finance, Govt. of India.
- e) In case contamination is found in other crystalloid products under the above mentioned rate contract, the Performance Bank Guarantee (PBG) submitted by M/s Pentagon Labs Limited will be forfeited.

This order is being issued after considering all facts, documents, hearings, and applicable rules. The decision is based on the repeated supply of sub-standard quality products that compromise patient safety and violate contractual obligations, as detailed above.

This issues with the approval of the Competent Authority.

sd/-
Medical
Superintende
nt
Main
Hospital,
AIIMS,
(For and on
behalf of the
Director,
AIIMS, New
Delhi)

Attached: **NOTICE OF TERMINATION OF CONTRACT AND DEBARMENT.**

Copy to:

1. PPS to Director, AIIMS, New Delhi
2. PS to Addl. Director (Admin), AIIMS, New Delhi
3. PS to Sr. Financial Advisor, AIIMS, New Delhi
4. All Chief of Centers, AIIMS, New Delhi
5. All Senior Stores Officer/ Store Officer/ Assistant Store Officer, AIIMS, New Delhi
6. Stores Accounts Section, AIIMS, New Delhi
7. Professor In-Charge, Computer Facility: with request to upload the order on AIIMS website.



Debarment Letter_0001.pdf

5 MB
